A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.

Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, Rusch VM, Ladanyi M, Rizvi NA, Schwartz LH
Clin Cancer Res. 2010 16 (18): 4647-53

PMID: 20534736 · PMCID: PMC2940965 · DOI:10.1158/1078-0432.CCR-10-0125

PURPOSE - Tissue biomarker discovery is potentially limited by conventional tumor measurement techniques, which have an uncertain ability to accurately distinguish sensitive and resistant tumors. Semiautomated volumetric measurement of computed tomography imaging has the potential to more accurately capture tumor growth dynamics, allowing for more exact separation of sensitive and resistant tumors and a more accurate comparison of tissue characteristics.

EXPERIMENTAL DESIGN - Forty-eight patients with early stage non-small cell lung cancer and clinical characteristics of sensitivity to gefitinib were studied. High-resolution computed tomography was done at baseline and after 3 weeks of gefitinib. Tumors were then resected and molecularly profiled. Unidimensional and volumetric measurements were done using a semiautomated algorithm. Measurement changes were evaluated for their ability to differentiate tumors with and without sensitizing mutations.

RESULTS - Forty-four percent of tumors had epidermal growth factor receptor-sensitizing mutations. Receiver operating characteristic curve analysis showed that volumetric measurement had a higher area under the curve than unidimensional measurement for identifying tumors harboring sensitizing mutations (P = 0.009). Tumor volume decrease of >24.9% was the imaging criteria best able to classify tumors with and without sensitizing mutations (sensitivity, 90%; specificity, 89%).

CONCLUSIONS - Volumetric tumor measurement was better than unidimensional tumor measurement at distinguishing tumors based on presence or absence of a sensitizing mutation. Use of volume-based response assessment for the development of tissue biomarkers could reduce contamination between sensitive and resistant tumor populations, improving our ability to identify meaningful predictors of sensitivity.

©2010 AACR.

MeSH Terms (16)

Antineoplastic Agents Biomarkers, Pharmacological Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung Disease Progression Drug Resistance, Neoplasm Gefitinib Humans Imaging, Three-Dimensional Lung Neoplasms Pilot Projects Prognosis Quinazolines Sensitivity and Specificity Tomography, X-Ray Computed Tumor Burden

Connections (1)

This publication is referenced by other Labnodes entities: